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Abstract
Cartilage and endochondral bone development require SOX9 activity to regulate chondrogenesis, chondrocyte
proliferation, and transition to a non-mitotic hypertrophic state. The restricted and reciprocal expression of the collagen
X gene, Col10a1, in hypertrophic chondrocytes and Sox9 in immature chondrocytes epitomise the precise spatiotemporal
control of gene expression as chondrocytes progress through phases of differentiation, but how this is achieved is not clear.
Here, we have identified a regulatory element upstream of Col10a1 that enhances its expression in hypertrophic
chondrocytes in vivo. In immature chondrocytes, where Col10a1 is not expressed, SOX9 interacts with a conserved sequence
within this element that is analogous to that within the intronic enhancer of the collagen II gene Col2a1, the known
transactivation target of SOX9. By analysing a series of Col10a1 reporter genes in transgenic mice, we show that the SOX9
binding consensus in this element is required to repress expression of the transgene in non-hypertrophic chondrocytes.
Forced ectopic Sox9 expression in hypertrophic chondrocytes in vitro and in mice resulted in down-regulation of Col10a1.
Mutation of a binding consensus motif for GLI transcription factors, which are the effectors of Indian hedgehog signaling,
close to the SOX9 site in the Col10a1 regulatory element, also derepressed transgene expression in non-hypertrophic
chondrocytes. GLI2 and GLI3 bound to the Col10a1 regulatory element but not to the enhancer of Col2a1. In addition to
Col10a1, paired SOX9–GLI binding motifs are present in the conserved non-coding regions of several genes that are
preferentially expressed in hypertrophic chondrocytes and the occurrence of pairing is unlikely to be by chance. We
propose a regulatory paradigm whereby direct concomitant positive and negative transcriptional control by SOX9 ensures
differentiation phase-specific gene expression in chondrocytes. Discrimination between these opposing modes of
transcriptional control by SOX9 may be mediated by cooperation with different partners such as GLI factors.
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Introduction
Chondrogenesis and the formation of bone by endochondral
ossification depend on progressive steps of cell differentiation.
Mesenchymal cells condense and differentiate into chondrocytes in
a pattern that will define the eventual shape of the different skeletal
elements. These chondrocytes proliferate, mature, exit the cell cycle
and become prehypertrophic. The differentiation program culminates
in the terminal differentiation and apoptosis of post-mitotic
hypertrophic chondrocytes [1]. This differentiation program is
controlled by members of the SOX and RUNX families of
transcription factors and the integration of multiple signaling pathways
mediated by Indian hedgehog (Ihh), parathyroid hormone-related
protein (PTHrP), Wnts, BMPs, and Notch (reviewed in [2]). PTHrP
and Ihh are two important players which interact to form a feedback
loop that controls the pace of the differentiation program [3].
Sox9 is essential for chondrogenesis and chondrocyte differen-
tiation [4–6]. It is essential for mesenchymal condensation prior to
chondrogenesis, and in its absence chondrocyte differentiation
fails. Inactivation of Sox9 in chondrocytes at different stages of
differentiation suggests that its expression is essential for the
survival of chondrocytes so that they can progress to hypertrophy
[5–7]. Mutations in SOX9 are associated with the human skeletal
malformation syndrome, campomelic dysplasia, in which skeletal
abnormalities can be attributed to the disruption of the
chondrogenic differentiation program due to failure to express
SOX9 target genes. Upon hypertrophy, chondrocytes down-
regulate Sox9 expression [8,9], which is believed to mark the end of
SOX9 control in the growth plate.
Despite the wealth of information about spatial and temporal
gene expression patterns in the developing growth plate, it is not
clear how transcriptional controls achieve appropriate and specific
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gene expression during chondrocyte differentiation. SOX9
activates many genes expressed in proliferating chondrocytes,
including the extracellular matrix (ECM) genes Col2a1, Col9a1,
Col11a2, Acan (aggrecan) and Cd-rap/Mia1 [10–15]. For the Col2a1
gene, which is expressed most strongly in proliferating chondro-
cytes, SOX9 directly transactivates the gene in vivo via a conserved
enhancer sequence within the first intron [10,11].
The collagen X gene, Col10a1, is a hypertrophic chondrocyte
specific marker. The specificity and reciprocity of Sox9 and
Col10a1 expression epitomise the strict control of temporal and
differentiation phase-specific gene expression in the growth plate.
Col10a1 is ideal for studying transcriptional regulation because as
well as its highly specific expression pattern, over-expression or
loss-of-function does not disrupt chondrocyte differentiation.
These properties simplify interpretation of changes in gene
expression resulting from perturbing transcriptional control [16–
18]. Here, we examined the transcriptional controls that restrict
Col10a1 expression to hypertrophic chondrocytes. We found that
SOX9 coordinates gene expression during chondrocyte differen-
tiation through both transcriptional activation and repression.
Discrimination between these opposing actions is probably
achieved by cooperation between SOX9 and different partners
such as GLI factors.
Results
Proliferating and hypertrophic chondrocytes show
overlapping and different protein binding domains in the
Col10a1 enhancer
Previous cell transfection studies identified an enhancer element
upstream of human COL10A1 [19]. This element is highly
conserved in mammals and corresponds to a 640 bp region
between24.3 and23.6 kb of the mouse Col10a1 gene (designated
element A) (Figure 1A and 1B). We used DNase I footprinting
assays to test the configurations in which the element A sequences
could be directly bound by nuclear factors derived from
chondrocytes at different differentiation states (Figure 2A). Extracts
from hypertrophic chondrocytes MCTs, but not fibroblasts COS-1
or osteoblasts MC3T3-E1, protected six blocks of sequence (H1–
H6). Noticeably, four different blocks (P1–P4) that partially
overlap H1–H4 were protected by extracts from the proliferating
chondrocyte/chondrosarcoma cell line CCL (Figure 1C and
Figure 2A). Since proliferating chondrocyte/chondrosarcoma cells
do not express Col10a1 (Figure S1A), these results suggest that in
these cells, the proteins that bind to element A may contribute to
the repression of Col10a1.
SOX9 binds to Col10a1 element A in proliferating
chondrocytes
We and others previously showed that SOX9 regulates
COL2A1/Col2a1 gene via a functional in vivo binding site in the
intron 1 enhancer element [10,11]. We identified the same
SOX9-binding sequence within the Col10a1 element A (Figure 1C
and Figure 2B). This site, COL2C1, lies on a region in block P3
that is not protected in hypertrophic chondrocytes, and is
adjacent to a stretch of thymidine/guanine-rich (TG-rich)
sequence. Electromobility shift assays revealed that SOX9 bound
to this SOX9/TG-rich motif with a similar affinity as to the
COL2A1 enhancer element (Figure S1C, S1E, S1F) [10] and the
interaction involved dimeric binding (Figure 2C, cf. lane 3–4).
SOX9 also interacted with the TG-rich motif but with a lower
affinity than with the consensus SOX9 site. Mutation of the TG-
rich motif reduced the overall SOX9 binding to the P3 element
(Figure 2C, cf. lanes 6–10). The TG-rich motif resembles a
RUNX binding consensus sequence, but we found that RUNX2
did not interact with this motif effectively compared with its
binding to the RUNX site in the Bglap (osteocalcin) enhancer
(Figure 2D). Chromatin immunoprecipitation (ChIP) assays using
extracts from E13.5 mouse limb, a stage at which the cartilage
anlagen is largely composed of immature chondrocytes, con-
firmed specific SOX9 binding to the Col10a1 element A and the
Col2a1 enhancer in vivo (Figure 2E).
SOX9/TG-rich motif is required for appropriate Col10a1
expression
The paired SOX9 binding sequences in element A are
separated by 4 bp, a distance similar to that between the paired
SOX-like consensus sequences in Col2a1, Col9a1, and Acan that
mediate transactivation of expression [15]. We tested the in vivo
role of element A and the effects of SOX9/TG-rich motif
mutations on the expression of Col10a1 mini-genes (Figure 3A) in
transgenic mice. We have previously shown that a Flag-tagged
Col10a1 vector Col10Flag (formerly known as FColX) is expressed
in P10 hypertrophic chondrocytes [18]. Here, we show that in
E15.5 humeri, the Col10Flag transgene was expressed in islands in
prehypertrophic and hypertrophic chondrocytes in the upper
hypertrophic zone (Figure 3B, e). In two independent mouse lines,
a transgene comprising element A fused to the Col10Flag
(Col10Flag-E) was expressed in a similar pattern as Col10Flag,
but was significantly more strongly expressed than Col10Flag in all
hypertrophic chondrocytes (Figure 3B, i), reflecting the enhancer
activity of element A (see also Figure S2). However, mutation of
the SOX9 site in element A (Col10Flag-ED1) resulted in marked
expansion of the expression domain of the transgene, extending
from the hypertrophic zone to the proliferating zone in the
majority of transgenic fetuses (71.4%) (compare Figure 4, a with
Author Summary
Chondrogenic differentiation is a key process in the
formation of endochondral bone. Despite the wealth of
information about gene expression patterns and signaling
pathways important for this process, it is not clear how
differentiation state-specificity of transcription is con-
trolled. The transcription factor SOX9 regulates chondro-
cyte differentiation, proliferation, and entry into hypertro-
phy and is highly expressed in immature/proliferating
chondrocytes. It directly transactivates Col2a1, enhancing
this gene’s expression in immature/proliferating chondro-
cytes. The Col10a1 gene is specifically expressed in
hypertrophic chondrocytes in which Sox9 is downregulat-
ed. How is differentiation phase-specific transcription of
genes controlled in chondrocytes, particularly during
hypertrophy? We found that SOX9 directly represses
Col10a1 expression in immature/proliferating chondro-
cytes of the growth plate, so that its expression is
restricted to hypertrophic chondrocytes. Discrimination
of this concomitant opposing transcriptional control may
involve cooperation between SOX9 and different partners
such as GLI factors (effectors of hedgehog signaling). SOX9
control of chondrocyte maturation therefore may be
integrated with hedgehog signaling. Mutations in human
SOX9 cause the skeletal malformation syndrome campo-
melic dysplasia, which is attributed to the disruption of the
chondrogenic differentiation program because of failure to
express SOX9 target genes. This interpretation should be
revised to include inappropriate expression of genes
normally repressed by SOX9.
SOX9 Is an Activator and Repressor in Chondrocytes
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Figure 1. Conserved non-coding regions in COL10A1. (A) Global alignment of COL10A1 loci was performed using mammalian genomes. The
translated regions in exons 2 and 3 of COL10A1 are highly conserved (deep blue). Element A of mouse Col10a1, which corresponds to the human
enhancer, is located in the nearest conserved upstream non-coding region (pink). The untranslated regions (light blue) are poorly conserved in
opossum. The mouse genome serves as the base sequence for alignment. Op: opossum; Ca: canine; Bo: bovine; Hu: human. (B) The 640 bp element A
is located between 24286 and 23646 bp of mouse Col10a1. (C) Conserved non-coding regions in mammalian COL10A1. Alignment showed that the
functional SOX9 binding site (COL2C1) is conserved in the mammalian COL10A1 enhancers together with the adjacent TG-rich sequence. The
SOX9 Is an Activator and Repressor in Chondrocytes
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Figure 3B, i) and in almost all the Sox9-expressing chondrocytes in
the rest (Figure 4, e). Expansion of transgene expression in
proliferating chondrocytes was also noted but was less marked
when the TG-rich motif in element A was mutated (Col10Flag-
ED2) (compare Figure 4, m and i with a and e). Mutation of either
SOX9 or the TG-rich motif did not abrogate transgene
expression in hypertrophic chondrocytes. Together, these obser-
vations suggest that element A contains both positive and
negative regulatory sequences, and that mutations in the
SOX9/TG-rich motif in element A might disrupt SOX9-
mediated repression in immature chondrocytes.
SOX9 is a negative regulator of Col10a1
To test whether SOX9 negatively regulates Col10a1, we
established a cell line from hypertrophic chondrocytes MCTs
which expressed the Col10Flag-E transgene at the non-permissive
(growth-arrest) temperature (Figure 5A). Similar to previous
findings for dedifferentiated chondrocytic cells MC615, over-
expression of SOX9 in MCTs did not transactivate endogenous
Col2a1 [20]. However, SOX9 over-expression significantly down-
regulated expression of both endogenous Col10a1 and the
exogenous Col10Flag-E reporter (Figure 5B) supporting the notion
that SOX9 is a negative regulator of Col10a1. To study the
regulation in vivo, SOX9 was ectopically expressed in hypertro-
phic chondrocytes in mice. Mice expressing Cre recombinase
inserted into the endogenous Col10a1 gene (Col10a1-Cre) [21]
were crossed with transgenic mice carrying a single copy of a Cre-
inducible Sox9-IRES-EGFP expression construct (Z/Sox9) [22]
(Figure 5C). In Col10a1-Cre;Z/Sox9 mice, Sox9 and the linked Egfp
reporter gene were activated in the hypertrophic chondrocytes at
E17.5 in the anterior ribs (Figure 5D, h, i). These mice displayed
an expanded hypertrophic zone and reduced Col10a1 expression
(Figure 5D, e, k). Interestingly, we also found that transcription of
Cre from the Col10a1 locus was reduced in Col10a1-Cre;Z/Sox9
mice (Figure 5D, a, g). Col2a1 expression in Col10a1-Cre;Z/Sox9
mice hypertrophic chondrocytes was not up-regulated suggesting
the reduction of Col10a1 expression in these cells was not because
of a reversion to a more immature state (Figure 5D, d, j). In the
ribs Runx2 was expressed predominantly in osteoblasts, the
perichondrium flanking the hypertrophic chondrocytes, and in
prehypertrophic chondrocytes (Figure 5D, f). Expression was low
in hypertrophic chondrocytes. There was no significant change in
Runx2 expression in prehypertrophic and hypertrophic chondro-
cytes in Col10a1-Cre;Z/Sox9 mice (Figure 5D, l). Collectively,
these data suggest that SOX9 negatively regulates Col10a1 gene
expression independent of Runx2.
GLI factors bind and regulate Col10a1 in proliferating
chondrocytes
The specificity of SOX protein action is known to be achieved
through interaction with cell-specific partners [23,24]. We
questioned whether concomitant transactivation of Col2a1 and
repression of Col10a1 by SOX9 in proliferating chondrocytes
could be mediated by different combinations of cofactors. ChIP
assays in E13.5 mouse limb chondrocytes or CCL cells revealed
similar interactions of TRAP230/MED12, a mediator of SOX9
activity [25], and of TRPS1, a GLI3-interacting repressor
[26,27], with both the Col10a1 element A and the Col2a1
enhancer (Figure 6A, upper panel). On the other hand, the
transcriptional co-repressor, histone deacetylase HDAC4 [28]
immunoprecipitated neither element. GLI1, GLI2 and GLI3 are
effectors of Hh signaling which controls chondrocyte proliferation
and maturation [29]. GLI1 is a transactivator expressed in
proliferating chondrocytes and perichondrial tissue flanking the
prehypertrophic and hypertrophic zones [30] whereas GLI2 and
GLI3 can act as repressors and are predominantly expressed in
non-hypertrophic chondrocytes and are down-regulated in
hypertrophic chondrocytes [29,31]. Since there is a conserved
GLI-binding site near the SOX9/TG-rich motif in the same
footprint block P3 (Figure 1C), we examined whether GLI1,
GLI2 and GLI3 can interact with the element A. Strikingly, while
SOX9 bound to both the Col10a1 element A and Col2a1
enhancer, GLI2 and GLI3 associated with only Col10a1 element
A (Figure 6A, lower panel). GLI3 interacted the most with element
A, while GLI1 interaction was much less. Quantitative ChIP
assays confirmed the preferential interaction (Figure 6B). From
these results we hypothesized that GLI proteins may repress
Col10a1 expression. To test this in vivo, we examined the impact
on transgene expression of mutating the GLI-binding site in
element A (Col10Flag-ED3). Consistent with our hypothesis, the
majority of fetuses (7 out of 10) expressing Col10Flag-ED3 showed
distinct islands of transgene misexpression in non-hypertrophic
chondrocytes (Figure 6C, e, f). Mutating all three sites (GLI,
SOX9, TG-rich) in the transgene (Col10Flag-ED4) did not restrict
the expansion of the expression domain to proliferating
chondrocytes in all the expressing transgenic fetuses obtained
(Figure 6C, i, j). Indeed in the majority of these expressing fetuses
(3 out of 5), transgene expression extended throughout the entire
cartilage zones. Thus mutation of the GLI site alone had a similar
derepressing effect as mutating the SOX9/TG-rich motif and
mutating all the motifs did not restrict expression but resulted in
more extensive mis-expression. This is consistent with a model
whereby SOX9 and GLI act cooperatively to repress Col10a1
transcription.
To assess whether the cooperation of SOX9 and GLI2/3 is a
potential common mechanism for restricted or preferential gene
expression in hypertrophic chondrocytes, we searched in silico for
this configuration of binding sites in genes, other than Col10a1,
that have strong and specific up-regulation in hypertrophic
chondrocytes (HC genes) in the growth plate. Six of 11 HC genes
analyzed, namely Col10a1, Bmp2, Hdac4, Mef2c, Runx2, and Sox4,
possess the linked SOX9 and GLI sites (,100 nt spacing) in the
inter- or intragenic conserved non-coding regions (Figure 7A and
Figure S3). In contrast, these sites were absent from most of the
genes tested (12 out of 14) that were expressed in proliferating but
not (or down-regulated) in hypertrophic chondrocytes (PC genes).
These include known SOX9 targets: Col2a1, Col9a1, Col11a2, Acan,
and Mia1 (see Figure 7A legend for all negative genes). The
exceptions were Sox5 and Sox6 (Figure 7A and Figure S3). To
investigate whether the over-representation of linked SOX9-GLI
sites in the HC genes but not the PC genes occurs by chance, we
performed a hypergeometric test to calculate the probability of
finding 6 or more SOX9-GLI site-containing genes out of 11
genes randomly sampled from the mouse genome. For the HC
genes, the results showed that the occurrence of 6 or more genes
with associated conserved SOX9-GLI sites is unlikely to occur by
positions of the chondrocyte-specific binding motifs H1–H4 and P1–P4 deduced from DNase I footprinting are indicated. The primer sequences used
in the chromatin immunoprecipitation are indicated in blue boxes. Consensus GLI and TCF binding sites were identified near the SOX9/TG-rich motif.
Sequences involved in mutagenesis are shaded in blue. Only the mismatched nucleotides are shown in the aligned sequence.
doi:10.1371/journal.pgen.1002356.g001
SOX9 Is an Activator and Repressor in Chondrocytes
PLoS Genetics | www.plosgenetics.org 4 November 2011 | Volume 7 | Issue 11 | e1002356
chance (p=0.0000201) (Figure 7B). For the PC genes, the p-value
was 0.17, which is comparable to random occurrence. Further-
more the frequency of the presence of SOX9-GLI sites for HC
genes (6/11) was significantly higher than that for PC genes (2/14)
(Fisher’s test p=0.043, one tailed). This suggests that the linked
SOX9-GLI sites are preferentially associated with the HC genes.
Figure 2. Interaction of SOX9 with a conserved upstream element of Col10a1. (A) A fragment of element A (24239 to 23933 bp) was
digested with increasing concentrations of DNase I in the presence of extract buffer alone or nuclear extracts (NE) from COS-1 (Fib), MCTs (HC),
MC3T3-E1 (Ost), or CCL cells (PC), or used to produce the G/A ladder (L). (B) Diagram of interaction between cell type-specific nuclear factors (ovals)
and element A based on the footprints. A SOX9 binding site is located in P3. (C) Electromobility shift assay (EMSA) of the interaction of the SOX9/TG-
rich motif in element A of Col10a1 (C10C1) with SOX9. The interaction involved dimeric SOX9 binding (C10C1-SOX92). Complexes formed between
SOX9 and C10C1 were challenged with SOX9 antibody (lane 4) and competitors of wild-type or mutant sequence (lane 5–10). Mutation of the SOX9
site and the adjacent TG-rich motif reduced SOX9 binding. (D) In EMSA, RUNX2 interacted with the Bglap (Osteocalcin) enhancer probe (OSE2)
containing the osteoblast-specific RUNX2 binding consensus motif. The interaction was challenged with RUNX2 antibody (lane 4) and competitors of
wild-type or mutant OSE2 (lane 5–8), or C10C1 (lane 9–10), at 10- or 100-fold excess. (E) Chromatin immunoprecipitation (ChIP) assay demonstrating
SOX9 interaction with the SOX9/TG-rich binding site. Real-time PCR was performed to amplify element A of Col10a1 as well as sequences from the
Col2a1 enhancer and Crygb (c-b-crystallin) promoter. See also Figure S1.
doi:10.1371/journal.pgen.1002356.g002
SOX9 Is an Activator and Repressor in Chondrocytes
PLoS Genetics | www.plosgenetics.org 5 November 2011 | Volume 7 | Issue 11 | e1002356
Discussion
The positive and negative mechanisms mediating the stage-
specific transcription of genes within the growth plate are not well
defined, partly because of the difficulty in distinguishing direct
effects on transcription from the consequences of abnormal
differentiation. In this study we have exploited the specificity of
Col10a1 expression in hypertrophic chondrocytes and the fact that
manipulating its expression in vivo has no overt effect on
differentiation, to dissect these transcriptional controls. We
provide new insight into how differentiation stage-specific gene
expression is achieved in the growth plate, presenting in vitro
and in vivo evidence that SOX9, in addition to its known role as
a transactivator of many genes preferentially expressed in non-
hypertrophic chondrocytes, such as Col2a1, directly represses
expression of Col10a1 at a stage prior to the onset of
hypertrophy and subsequently in proliferating chondrocytes.
This discovery extends our understanding of the mecha-
Figure 3. Element A enhances Col10a1 transgene expression in the growth plate. (A) Diagram showing the Flag-tagged Col10a1 mini-genes
for transgenesis. The constructs included all introns and a 59 flanking region up to 22.07 kb (green). At the 59 end, the constructs were combined
with the 640 bp element A (orange) containing wild-type sequence (E). (B) The expression pattern of the Flag-tagged Col10a1 mini-genes (a,e,i) was
compared with that of endogenous Col10a1 (b,f,j), Runx2 (c,g,k), and Sox9 (d,h,l) by in-situ hybridization of proximal humerus in E15.5 expressing
fetuses. (a–d) Tissue-specific Col10a1 expression in hypertrophic zone of non-transgenic littermate (NT) was shown. (e–h) In the absence of element A,
patchy expression of the mini-gene was observed in prehypertrophic and upper hypertrophic chondrocytes. (i–l) Addition of element A resulted in
marked up-regulation of mini-gene expression in the whole hypertrophic zone (*). Since expression of Col10a1 was used as readout of derepression,
Runx2 was used as an alternative marker of hypertrophic chondrocytes. In addition to hypertrophic chondrocytes, expression of Runx2 was noted in
the trabecular bone and in the prehypertrophic chondrocytes. The prehypertrophic and hypertrophic zones (encircled) were identified based on
Runx2 expression. PC, proliferating chondrocytes; PHC, prehypertrophic chondrocytes; HC, hypertrophic chondrocytes.
doi:10.1371/journal.pgen.1002356.g003
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Figure 4. Mutation of SOX9 binding consensus results in derepression of Col10a1 transgene expression in vivo. The expression pattern
of mutant Flag-tagged Col10a1 mini-genes, in which the SOX9 site (Col10Flag-ED1) or the TG-rich motif (Col10Flag-ED2) within the element A was
mutated, was examined by in-situ hybridization of proximal humeri in E15.5 expressing fetuses. In a major (5/7) portion of Col10Flag-ED1 fetuses (a–d),
the expression in the proliferating zone (*) was relatively higher than in the hypertrophic zone. In a minor (2/7) portion (e–h), the expression was
predominant in nearly all immature chondrocytes (*). For Col10Flag-ED2, a minor (2/6) portion of fetuses (m–p) showed up-regulated expression in the
non-hypertrophic zone (*), while a major (4/6) portion showed relatively slight mis-expression (i–l). The prehypertrophic and hypertrophic zones are
encircled. PC, proliferating chondrocytes; PHC, prehypertrophic chondrocytes; HC, hypertrophic chondrocytes.
doi:10.1371/journal.pgen.1002356.g004
SOX9 Is an Activator and Repressor in Chondrocytes
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Figure 5. SOX9 directly represses Col10a1 in hypertrophic chondrocytes. (A) Clonal cell line MCTs-F expressing the Col10Flag-E was
established from MCTs. (a) Immunohistochemistry indicated up-regulated Flag-tagged collagen X in growth arrested MCTs-F cells. (b) Flag signal in
the cytosolic vesicles. (B) MCTs-F cells transfected with SOX9 expression vector (pSG-Sox9), or empty vector (pSG5). Expression of Col10a1 and
Col10a1-Flag (36 bp longer in amplicon) was significantly reduced upon exogenous Sox9 expression (*, p#0.02). No RNA (2) or RNA from E16.5
Col10Flag-E expressing fetus (+) was used as control. (C) Strategy for activating ectopic Sox9 expression in hypertrophic chondrocytes. The pZ/Sox9
SOX9 Is an Activator and Repressor in Chondrocytes
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nisms by which SOX9 controls chondrocyte differentiation
phase-specific gene expression.
We have identified a conserved regulatory sequence, element A,
that acts as an enhancer of Col10a1 expression in both cultured
cells and in vivo. This element contains a SOX9 binding sequence
that, when bound by SOX9, represses Col10a1 expression in
immature and proliferating chondrocytes. Since Sox9 is expressed
in non-hypertrophic chondrocytes but not in hypertrophic
chondrocytes, this repressive action of SOX9 restricts Col10a1
expression to hypertrophic chondrocytes.
SOX9 has been proposed to direct chondrogenic fate in osteo-
chondroprogenitor cells in part by interacting with RUNX2
[32,33]. SOX9 may inhibit chondrocyte hypertrophy in part via
activation of Bapx1 which represses Runx2 [34,35]. Previous in vitro
and in vivo studies suggest that Col10a1 expression is regulated
positively by Mef2c, Runx2/Cbfa1, and AP-1 members, which are
expressed in hypertrophic chondrocytes [19,36–38]. RUNX2 has
been shown to directly regulate the expression of Col10a1 [37].
The element A that we identified contains no conserved consensus
RUNX site. The RUNX2 site revealed by Zheng et al. [37] is
located within a poorly conserved region outside the element. Our
data showed that the ectopic expression of Col10a1 transgene in
non-hypertrophic chondrocytes does not require co-expression of
Runx2. In addition, RUNX2 is not expressed in the costal
hypertrophic chondrocytes and cultured hypertrophic chondro-
cytes MCTs (which is derived from costal cartilage), where Col10a1
expression is strong. Although real-time PCR showed levels of
Col10a1 was markedly reduced in P1 Runx2-null mice [37],
hypertrophic chondrocytes with strong Col10a1 expression do
develop in many cartilages in Runx2 null fetuses [39,40].
Collectively existing data suggest that RUNX2 together with
other factors regulate Col10a1 in vivo via promoting chondrocyte
hypertrophy or otherwise functions to initiate a cascade of
regulatory pathways that sustain Col10a1 expression in hypertro-
phic chondrocytes.
Previous in vitro studies in chicken have suggested that a
combined action of positive and negative DNA elements may
contribute to the hypertrophic chondrocyte-specific expression of
Col10a1 [41,42]; however, these chick Col10a1 elements are not
conserved in mammals. The enhancer element we identified is
highly conserved in mammals, but not in chicken, which agrees
with previous data [43]. This suggests that in both mammals and
chicken, Col10a1 transcription is restricted to hypertrophic
chondrocytes by repression, though by different cis-acting
elements. In the chicken, this repression may extend to non-
chondrogenic cell types [41]. We found no evidence to support
such a mechanism in the mouse since when we abolished the
interaction of SOX9 with the repressive element, we observed no
ectopic Col10a1 expression in non-chondrogenic cells.
Consistent with a role for SOX9 in repressing Col10a1 in vivo, we
have shown in Col10a1-Cre;Z-Sox9 mice, that activation of Sox9
expression in hypertrophic chondrocytes in costal cartilage caused
down-regulation of Col10a1. It is also notable that in a recent
report where Sox9 was over-expressed in hypertrophic chondro-
cytes in transgenic mice, expression of Col10a1 and the BAC-Col10-
Sox9 transgene appeared reduced in the hypertrophic chondro-
cytes [44]. In the same report Sox9 knockdown in cultured
chondrocytes did not affect Col10a1 expression [44]. By contrast
Yamashita et al. showed that shRNA knockdown of Sox9 can up-
regulate Col10a1 expression in primary costal chondrocyte culture,
and that over-expression of Sox9 can down-regulate it [35]. These
contradictory results may be related to the incomplete elimination
of SOX9 protein and the known dosage dependent requirement
for SOX9 action. A role for SOX9 as transcriptional repressor of
Col10a1 in non-hypertrophic chondrocytes is consistent with the
observation that COL10A1 expression was up-regulated in
cartilage isolated from SOX9 haploinsufficient campomelic dys-
plasia patients [33].
How may SOX9 act both as a transactivator and a repressor in
non-hypertrophic chondrocytes? It has been proposed that
interactions between specific partner factors stabilize SOX protein
binding to DNA and hence regulate target selection [24], thereby
determining cell specification, as exemplified by SOX2 in
embryonic stem cells and other systems [45]. Such selective
cooperation of protein binding partners may mediate the
concomitant positive and negative regulation of SOX9 target
genes in the same cell that contributes to specification of the
differentiation state (Figure 8). As illustrated in the schematic
(Figure 8), we propose that SOX9 mediates repression of Col10a1
in proliferating chondrocytes by selective cooperation with GLI
factors. Together with its role in activating Col2a1 and other
matrix genes, SOX9 therefore plays an important role in
maintaining chondrocytes in an immature non-hypertrophic state.
RUNX2 by contrast promotes chondrocyte hypertrophy.
SOX9 cannot regulate chondrocyte differentiation appropri-
ately without sonic hedgehog (Shh), which mediates the generation
of chondrogenic precursor cells [46], and Indian hedgehog (Ihh),
which regulates their proliferation and maturation [47]. GLI
proteins are the effectors of Hh signaling. Double knockout
mutants indicate that GLI2 has overlapping functions with GLI1
and GLI3 in skeletal and CNS development [48,49]. Binding of
Hh to its receptor, Patched, blocks the proteolytic processing of the
GLI transcription factors from active (GLIA) to repressive (GLIR)
forms, and the balance between these forms modulates hedgehog
target gene expression [50]. In the growth plate, GLI2A can
positively regulate chondrocyte hypertrophy and control vascular-
ization of the hypertrophic cartilage in endochondral ossification
[29,51]. GLI3, which acts mainly as a repressor, has been
suggested to inhibit chondrocyte hypertrophy [29,52] and it is
interesting that the highest interaction of element A was with
GLI3. Mau et al. reported that Gli2/3 null mutations altered the
expression domain of collagen X, but it was not possible to
distinguish whether this was due to a direct effect on Col10a1
transcription or more general perturbation of hypertrophy [29].
How the GLI factors interact with other regulatory factors or
genes in the chondrocyte differentiation program is not clear. Our
results are consistent with cooperation between SOX9 and the Hh
signaling pathway and suggest that SOX9 acts in synergy with
GLI2 and GLI3, probably their repressive forms GLIR, to repress
transcription in chondrocytes. Thus, reduced synergy between
GLIR and SOX9 may explain the accelerated chondrocyte
hypertrophy seen when Ptch1 is inactivated [53]. Over-represen-
tation of the SOX9-GLI paired consensus in a number of genes
that are preferentially expressed in hypertrophic chondrocytes and
construct consists of a LacZ and Sox9-EGFP expression cassette attached to a chicken b-Actin promoter (Pb-Actin)/CMV enhancer (Enh). The Sox9-EGFP
cassette is expressed after Cre-mediated recombination. (D) Cre-activated ectopic Sox9 expression in the hypertrophic zone of costal cartilage in
Col10a1-Cre;Z/Sox9 compound mutants at E17.5. Ectopic Sox9 expression (i, encircled) down-regulated Col10a1 (k, encircled) and Cre (g) in
hypertrophic chondrocytes, especially in the extended hypertrophic zone. The reduction of Col10a1 is not associated with change in Runx2
expression (l) in hypertrophic chondrocytes. PC, proliferating chondrocytes; PHC, prehypertrophic chondrocytes; HC, hypertrophic chondrocytes.
doi:10.1371/journal.pgen.1002356.g005
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Figure 6. GLI as SOX9 partner in Col10a1 repression. (A) ChIP assays with CCL cells (upper panel) and E13.5 mouse limbs (lower panel) using
various antibodies. The products were amplified with primers for element A of Col10a1 or enhancer element of Col2a1 in intron 1. Extract was
immunoprecipitated with rabbit IgG or without antibody (2) as negative reference. Extract was directly used in PCR as positive control (input). (B) The
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not in proliferating chondrocytes, suggests that SOX9 may use this
partnership to repress transcription of several genes in other
chondrocyte types. However this partnership may not be the
exclusive mechanism by which SOX9 acts to repress expression in
chondrocytes.
Hattori et al. have recently shown that SOX9 directly represses
Vegfa in cultured primary chondrocytes [44] by interacting with the
59 untranslated region of the gene. This agrees with our findings of
a repressive role of SOX9, however, we found no linked SOX9-
GLI binding sites near the Vegfa gene and a recent SOX9 ChIP-
on-chip study reported no in vivo interaction in Vegfa exon 1 [54].
A different mode by which SOX9 may repress gene expression
in chondrocytes has been proposed by Huang et al [55]. In their
model, SOX9 negatively regulates Ccn2 expression in non-
hypertrophic chondrocytes via binding to overlapping binding
sites for SOX and TCF/LEF, thereby interfering with binding of a
TCF/LEF/b-catenin transactivation complex. Reduction of
SOX9 upon hypertrophy allows this TCF/LEF/b-catenin com-
plex to activate Ccn2 expression [55]. However, Ccn2 is also
expressed in resting zone chondrocytes in the epiphyses of the
growth plate and it is not clear why SOX9 does not repress the
gene in these cells. We identified a conserved TCF consensus site
in Col10a1 element A, but this is unlikely to interfere with SOX9
binding since it is located 59 bp downstream of the functional
SOX9-GLI motif, unlike in Ccn2 where the SOX and TCF/LEF
sites overlap (Figure 1C). This suggests that the model proposed by
Huang et al. does not apply to Col10a1 element A-mediated
repression of transcription.
It is also possible that SOX9 and GLI cooperate to activate or
repress transcription depending on context. While our data
implicate a cooperation of SOX9 with GLI factors in transcrip-
tional repression, this association between SOX9 and GLI may
not be restricted to negative regulation. Amano et al. have recently
reported that GLI2 cooperates with SOX9 to transactivate the
Pthlh gene (also known as PTHrP) in chondrocyte culture without
direct binding to the gene [56]. However the expression patterns
of Sox9 and Pthlh are mutually exclusive in the developing growth
plate, Pthlh being expressed mainly in the perichondrium and only
at extremely low levels in proliferating chondrocytes [57,58]. This
contradiction may reflect differences between in vitro assays and
regulation in vivo, and it is also unclear whether the expressed GLI2
was processed to a repressor form or not in these cells. The
observed stimulation of Pthlh promoter activity in the cultured
chondrocytes could therefore be attributable to over-expression of
GLI2 which persisted largely as the activated form GLI2A.
However this report does raise the possibility of a context
dependent SOX9-GLI partnership that mediates either transacti-
vation or repression.
Sox9 has been suggested to act upstream of Sox5 and Sox6 in
chondrogenesis [6,46]. The presence of conserved SOX9–GLI
sites in the Sox5 and Sox6 genes suggests their expression in
proliferating chondrocytes may be positively controlled via
cooperation of SOX9 with GLIA or GLI1, an activator that
reinforces GLIA function. Hence, the roles played by SOX9 in
transcriptional regulation may be determined by context—
partnering with GLIA/GLI1 favours transactivation, with GLIR
favours repression. Alternatively, as discussed above, the mode of
regulation might depend on whether intermediate factors are
present to interfere with the SOX9-GLI interaction. Interestingly,
while there is a linked SOX9-GLI motif in Sox6, a conserved TCF
site occurs between the SOX9 and GLI sites (Figure S3).
Cooperation between SOX9 and TCF/LEF/b-catenin might
therefore abrogate cooperative repression by SOX9 and GLI and
transactivate Sox6 in proliferating chondrocytes.
Validation of these different modes of cooperative regulation by
SOX9 and GLI factors in vivo would require the generation and
analyses of compound null or conditional knockout mutants;
however, the consequent dysregulation of chondrogenesis and
impact on cell survival would make it impossible to distinguish
changes in transcriptional control from effects on differentiation.
For example, Sox9 is essential for chondrogenesis and Sox9
conditional null chondrocytes undergo apoptosis and as a
consequence, hypertrophy with the characteristic activation of
Col10a1 expression, fails to occur [4,7,59]. Because inactivation of
Col10a1 does not disrupt the chondrogenic program, it provides an
ideal system and tools to interrogate the transcriptional controls
governing specificity of gene expression within the growth plate,
independent of changes in chondrocyte differentiation. Important
questions to be addressed in future are the identities and diversity
of SOX9 partnerships and how the activity of SOX9 and its
partners is modulated. In early myogenic differentiation, SOX9
and Smad3 have been reported to prevent premature expression
of a-sarcoglycan gene expression by synergistic repression in a
transforming growth factor b dependent manner [60] suggesting
negative transcriptional regulation by SOX9 and its partners may
be more common. The transactivation of Matn1 in chondrocytes
by SOX9 can be modulated by combined action of L-SOX5,
SOX6 and NFI factors [61]. Whether control of transcription by
the SOX9-GLI partnership can be modulated by additional
factors is an important question to be addressed in future.
In summary, our study implicates a complex regulatory function
for SOX9 whereby it acts with different partners to orchestrate
activation and repression of transcription in the chondrogenic
differentiation pathway. Mutations in human SOX9 cause the
skeletal malformation syndrome campomelic dysplasia which is
attributed to the disruption of the chondrogenic differentiation
program because of failure to express SOX9 target genes. This
interpretation may need to be revised to include inappropriate
expression of genes normally repressed by SOX9.
Materials and Methods
Bioinformatics analysis
COL10A1 sequences were aligned using LAGAN and PipMaker.
The conserved SOX9 binding sites (COL2C1 and COL2C2) [10]
were identified by rVISTA. The UCSC Mouse 30-Way Multiz
Alignment data and a custom Perl script were used to identify
human-mouse perfectly conserved SOX9, GLI, and TCF sites
with a maximum spacing of 100 bp in the inter- and intra-genic
non-coding regions. Conservation percentage of sequence span-
specific interaction of GLI with Col10a1 element A was validated in CCL cells by quantitative ChIP assay with real-time PCR. The degree of enrichment
was calculated by normalization of readouts to that of IgG control. (C) The expression of Col10a1 mini-genes with mutation in the GLI site was
examined by in-situ hybridization of proximal humeri in E15.5 fetuses. For transgene with GLI site mutation alone (Col10Flag-ED3), islands of
misexpression (Flag and Col10a1, arrows) were detected in the non-hypertrophic chondrocytes in most (7/10) expressing fetuses (e–h), while the rest
showed milder mis-expression (not shown). For the transgene with a mutation in both the GLI site and the SOX9/TG-rich motif (Col10Flag-ED4), the
majority of expressing fetuses (3/5) showed strong and extensive mis-expression (*) (i–l), while the rest showed relatively little mis-expression. Non-
transgenic littermate (NT) is shown as control (a–d). The prehypertrophic and hypertrophic zones are encircled. PC, proliferating chondrocytes; PHC,
prehypertrophic chondrocytes; HC, hypertrophic chondrocytes.
doi:10.1371/journal.pgen.1002356.g006
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Figure 7. Differential presence of SOX9-GLI sites in proliferating and hypertrophic phase-specific genes. (A) Position, orientation, and
spacing of the conserved linked SOX9 (COL2C1 and COL2C2) and GLI binding sites within the inter- and intra-genic regions of genes preferentially
expressed in proliferating (PC) or hypertrophic (HC) chondrocytes. Numbers between the sites indicate the length of nucleotide spacing.
Conservation indicates the percentage of nucleotides and species conserved in the alignments spanning the SOX9 and GLI sites. The alignments were
based on multiz30way in UCSC genome browser and were simplified to only include sequences from mouse (M), human (H), chimpanzee (P), canine
(D), bovine (C), and opossum (O) genome. Genes tested but found negative include HC genes Bmp6, Cdkn1c, Loxl4, Spp1, and Vegfa as well as PC
genes Acan, Bmp7, Col2a1, Col9a1, Col9a2, Col9a3, Col11a1, Col11a2, Fgfr3, Fos, Mia1, and Sox9. (B) Left panel: Venn diagram showing frequency of
genes in the genome that contain perfectly conserved SOX9, GLI, or linked SOX9-GLI sites within the inter- and intra-genic regions. SOX9 and GLI sites
co-exist but are not linked in the majority of genes. Right panel: Number of HC, PC and all genes in the mouse genome with conserved SOX9-GLI sites
and p-values from hypergeometric test (HT, for the over-representation of positive HC and PC genes compared to the genome) and one-tailed
Fisher’s exact test (FET, for the difference in number of positive genes between HC and PC group). The test was based on all genes in the mouse
genome (32,120 genes). See also Figure S3 for alignment data of the linked sites.
doi:10.1371/journal.pgen.1002356.g007
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ning the SOX9 and GLI sites was calculated based on the number
of perfectly matched nucleotides among all the aligned species
(mouse, human, chimpanzee, canine, bovine, and opossum). From
the 32,120 genes in the mouse genome, the number of genes
containing conserved linked SOX9-GLI sites was found and used
as the reference frequency of such genes in the genome. Whether
the frequency of the presence of conserved SOX9-GLI sites in HC
or PC genes exceeded this reference frequency was assessed by the
hypergeometric distribution. The difference in the frequency of
the presence of SOX9-GLI sites in the HC and PC genes was
assessed by the Fisher’s exact test.
Cell culture and transfection
Hypertrophic chondrocyte cell line MCTs (gift of Ve´ronique
Lefebvre [62]) was transfected with pCol10Flag-E, pSG-Sox9 (gift
of Peter Koopman), or pSG5 expression vector using Fugene 6
(Roche). Expression of the exogenous collagen X from pCol10Flag-
E in MCTs cells was examined by immunohistochemistry using
anti-Flag M2 antibody (Sigma). CCL (gift of James Kimura [63]),
MCT3T3-E1, and COS-1 cells were cultured in DMEM
(Invitrogen) containing 10% FCS (Wisent) at 37uC at 5% CO2.
MCTs cells were normally cultured at 32uC at 5% CO2 for
expansion. Prior to assays, MCTs cells were cultured at 37uC for 1
day to induce growth arrest [62].
DNase I footprinting
A 300 bp DNA fragment within element A, corresponding to
24240 to 23935 bp of the mouse Col10a1, was used as probe.
[c-32P]ATP-labeled probes were incubated with nuclear extracts
from CCL, MCTs, MCT3T3-E1, or COS-1 cells in the presence
Figure 8. A model for SOX9 control of differentiation phase–specific gene expression in growth plate chondrocytes. As chondrocytes
mature during endochondral bone formation, the concomitant transactivation and repression of transcription of differentiation stage-specific genes
by SOX9 is exemplified in Col10a1 and Col2a1. Sox9, its transactivation target Col2a1, as well as GLI2 and GLI3 are preferentially expressed by non-
hypertrophic chondrocytes. GLI3 is down-regulated when chondrocytes become prehypertrophic, while Sox9 and GLI2 expression is down-regulated
when chondrocytes reach hypertrophy [8,9,29]. Regulation of both Col10a1 and Col2a1 involves dimeric binding of SOX9. The GLI factors, and
possibly others, depending on the spatial context of their binding sites, are involved in the differential transcriptional control. MED12 and TRPS1 [25–
27] act as common mediators of transcriptional control. In proliferating chondrocytes, Col10a1 is repressed through binding of SOX9 and GLI2/3.
SOX9 negatively regulates Runx2 expression via Bapx1 in proliferating chondrocytes [34,35]. When chondrocytes mature and become
prehypertrophic, RUNX2 binding to SOX9 may reduce the amount available for Col10a1 [33] and, as GLI3 levels reduce, Col10a1 is partially
released from repression. Col2a1 transcription may be maintained due to stabilization of SOX9 binding by SOX5/6 [15]. In hypertrophic chondrocytes,
as SOX9-associated machinery diminishes, Col10a1 is completely de-repressed and is highly transactivated by factors such as RUNX2, MEF2C, AP-1.
Concomitantly Col2a1 expression is markedly decreased. SOX9 therefore controls differentiation-phase specific gene expression in chondrocytes
through direct and indirect mechanisms. PC, proliferating chondrocytes; PHC, prehypertrophic chondrocytes; HC, hypertrophic chondrocytes.
doi:10.1371/journal.pgen.1002356.g008
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of poly(dA?dT) at room temperature, followed by DNase I
digestion and denaturing PAGE.
Electromobility shift assays
COS-1 nuclear extracts over-expressing SOX9 and RUNX2
were pre-incubated with poly(dI?dC) or poly(dG?dC) at room
temperature, followed by reaction with [c-32P]ATP-labeled probes
with or without the presence of nucleotide competitors, or
antibodies for SOX9 (gift of Peter Koopman [64]) and OSF2/
RUNX2 (gift of Gerard Karsenty [65]), then subjected to non-
denaturing PAGE at room temperature. The sequences of
oligonucleotide COL2C1 and OSE2 were as previously described
[10,65].
Col10Flag transgenic mice
The mouse Col10a1 element A, a 640 bp-fragment located
between 24.2 and 23.6 kb, was cloned at the 59 end of the
pCol10Flag, previously known as FColX [18] consisting of 22070 to
+7176 bp mouse Col10a1 genomic sequence, to generate pCol10Flag-
E. The SOX9, TG-rich motif, and GLI binding sites in pCol10Flag-E
were mutated to generate the single site mutants – respectively
pCol10Flag-ED1, pCol10Flag-ED2, and pCol10Flag-ED3. All of these 3
motifs in pCol10Flag-E were mutated to generate pCol10Flag-ED4.
Col10a1-Cre;Z/Sox9 compound mutants
A 4.8 kb fragment of mouse genomic DNA (from 82 bp
upstream of the start of transcription of Sox9 to 1119 bp
downstream of the polyadenylation sequences), including the
Sox9 coding region, its two introns and 1.1 kb of 39 flanking
DNA, together with an IRES2-EGFP (Clontech) sequence
inserted between the Sox9 stop codon and the polyadenylation
site (at +3237 bp), was cloned downstream of the loxP-flanked
bgeo/3xpA of the pCall2 vector (gift of Andras Nagy [66]) to
create the pZ/Sox9 expression vector. pZ/Sox9 was transfected
into 129/SvEv-derived L4 embryonic stem (ES) cells by
electroporation and ES clones containing a single copy of the
transgene were injected into blastocysts followed by crossing of
chimeras with C57BL/6N mice to generate the mouse line Z/
Sox9. A mouse line carrying a single copy of pZ/Sox9 was
generated which was then crossed with Col10a1-Cre mice [21] to
obtain compound mutants.
Chromatin immunoprecipitation
CCL cell lysates or 13.5 dpc mouse limb tissue lysates were
cross-linked followed by lysis and sonication to yield 200–
500 bp DNA fragments then immunoprecipitation with anti-
bodies against acetylated histone H3/H4 (Ac-H3, Ac-H4)
(Upstate), HDAC4 (Abcam), GLI1, GLI2, GLI3 (all from
Santa Cruz), SOX9 (gift of Robin Lovell-Badge [67]),
TRAP230/MED12 (gift of Robert Roeder [25]), or TRPS1
(gift of Yasuteru Muragaki [26]). The target elements in
Col10a1, Col2a1, or Crygb genes were amplified by real-time or
standard PCR.
Gene expression analysis
In-situ hybridization was performed as previously described [9].
The probes used were pRK26 for Col10a1 [68], pWF21 for the
Flag sequence [18], p88 for full-length Sox9 (gift of Peter
Koopman), pBS-Cbfa1-Sh for full-length Runx2 (gift of Gerard
Karsenty), pWF98 for full-length Egfp, pBSII-Cre-frag for Cre (gift
of Andrew Groves), and pNJ61 for Col2a1 [9]. Gene expression in
cell culture was analyzed by RT-PCR.
For additional details of all experiments, see the Text S1.
Supporting Information
Figure S1 Additional gene/protein expression data and EMSA.
(A) Expression of Col2a1 and Col10a1 in CCL, MCTs, and
MC3T3-E1 was analyzed by RT-PCR. Controls were no RNA
(2) or RNA from mouse E17.5 embryo (+). Expression of
Col10a1 was found only in MCTs. (B) Western blot analysis
showed that both SOX9 and RUNX2 were highly expressed in
CCL but weakly in MCTs. (C) Expression of SOX9 in nuclear
(lane 3) and cytoplasmic (lane 4) fractions of pcDNA-Sox9
transfected COS-1 cells was compared with CCL (lane 1) and
untransfected COS-1 (lane 2) nuclear extracts by Western
blotting. (D) Expression of RUNX2 in nuclear (lane 3) and
cytoplasmic (lane 4) fractions of pcDNA-Cbfa1 transfected
COS-1 cells was verified by Western blotting. (E) A diagram
showing the sequences of oligonucleotides which contained
wild-type, mutant SOX9 and/or TG-rich motif for EMSA.
Only the mutated nucleotides were shown in the sequence of
competitors. (F) Intact DNA-binding property of SOX9 in
expressing nuclear extract was tested by its interaction with the
COL2A1 enhancer probe (COL2C1) in EMSA, in which the
retarded band was challenged with SOX9 antibody (lane 4),
unlabeled COL2C1 (lane 5–6), or Col10a1 element A C10C1
oligonucleotides (lane 7–8). The triangles represent increasing
concentration of competitors from 106 (lane 5,7) to 1006 (lane
6,8) excess.
(TIF)
Figure S2 In vivo transcriptional activity of Col10a1 element A.
(A) Expression pattern of Col10Flag-E in E15.5 transgenic fetus
(mid-sagittal plane) examined by in-situ hybridization using
digoxigenin-labeled probes. Flag expression was detected in the
hypertrophic chondrocytes of cervical pedicle (a) and developing
vertebrae (b). Weak expression was detected in the trabecular
bone of palate (c). No expression was found in the nucleus
pulposus (np) of the intervertebral disc (b), immature costal
cartilage (g, cc), brain (h), hair papillae (i), lung (m), aorta (n), or
myocardium (o). Expression of Col10a1 is shown for comparison
(d–f, j–l, p–r). No expression was found in erythrocytes or
nucleated blood cells (* in n and q). (B) In Col10Flag transgenic
fetus, strong expression of Flag was found in the ossifying zone of
pedicle (a, circled) and the trabecular bone of palate (b, circled).
Weak signal was detected in the prehypertrophic zone of the
pedicle cartilage (a, arrow). No expression was identified in tissue
other than cartilage and bone. Expression of Col10a1 is shown for
comparison (c–d).
(TIF)
Figure S3 Alignment data from SOX9-GLI site analysis.
Multispecies alignment of regions spanning the linked SOX9-
GLI sites are shown along with chromosomal location (Chr),
identical nucleotides (.), insertion or deletion (-), and unaligned
positions ( = ).
(PDF)
Text S1 Additional details of experiments.
(DOC)
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